California State Teachers Retirement System Decreases Stock Position in Cencora, Inc. $COR

California State Teachers Retirement System cut its stake in shares of Cencora, Inc. (NYSE:COR) by 2.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 282,224 shares of the company’s stock after selling 7,115 shares during the quarter. California State Teachers Retirement System’s holdings in Cencora were worth $88,658,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of COR. T. Rowe Price Investment Management Inc. boosted its stake in shares of Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares during the period. Norges Bank purchased a new position in shares of Cencora in the fourth quarter worth $822,506,000. Marshall Wace LLP increased its stake in shares of Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after buying an additional 1,241,186 shares during the last quarter. Finally, Viking Global Investors LP boosted its position in Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Cencora

In other Cencora news, Director Lauren M. Tyler bought 550 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of $270.23 per share, for a total transaction of $148,626.50. Following the purchase, the director owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $318.54 on Thursday. The business has a fifty day moving average price of $287.66 and a 200-day moving average price of $315.79. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a market capitalization of $61.97 billion, a PE ratio of 24.43, a PEG ratio of 1.77 and a beta of 0.58. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts expect that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora declared that its Board of Directors has authorized a share buyback program on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, May 15th. Cencora’s payout ratio is presently 18.40%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on COR shares. William Blair began coverage on shares of Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Evercore set a $360.00 price target on Cencora in a research report on Wednesday, April 8th. Wells Fargo & Company dropped their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Citigroup cut their price objective on Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Finally, Bank of America upped their target price on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.